Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
| Distributed by / for | PD-Rx Pharmaceuticals, Inc. |
| NDC | 43063-428-30 |
| Full product label | metFORMIN HCL ER USP 500 mg, a) 30 tablets (NDC: 43063-428-30); b) 60 tablets (NDC: 43063-428-60); c) 90 tablets (NDC: 43063-428-90); d) 120 tablets (NDC: 43063-428-98); e) 180 tablets (NDC: 43063-428-93); f) 500 tablets (NDC: 53746-0178-05), Rx only, PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 |
| Recalling firm | PD-Rx Pharmaceuticals, Inc. |
| Distribution | United States |
| Quantity | 3703 bottles |
| Recall initiated | 2020-06-05 |
| Report date | 2020-06-24 |
| Recall completed | 2021-11-08 |
| Recall number | D-1307-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Oklahoma City OK United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗